FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

The company’s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.

Also Read: Moderna’s mRNA Flu Vaccine Outperforms Standard Shots

“COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,” said Stéphane Bancel, CEO of Moderna. “We appreciate the FDA’s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.”

Moderna expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the ...